AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16099700 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin plus Aztreonam (V + A)
Number of subjects: 573
Study 12351535 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing used for 3 weeks (Group A)
Number of subjects: 45
Study 12351535 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing used for 3 days (Group B)
Number of subjects: 45
Study 12351535 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing with monitoring until a follicle of 13 mm (Group C)
Number of subjects: 45
Study 9471048 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection (ICI) of etilefrin
Number of subjects: 156
Study 7657903 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Guidelines Nutrition Care (PGC)
Number of subjects: 179
Study 7657903 — intervention group
Group type: COMPARATOR
Intervention: Basic Nutrition Care (BC)
Number of subjects: 179
Study 2676659 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fish oil concentrate (30% omega 3FAs) daily
Number of subjects: 10
Study 2676659 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g safflower oil daily
Number of subjects: 10
Study 2676659 — intervention group
Group type: COMPARATOR
Intervention: no supplementation (baseline)
Number of subjects: 10
Study 2676659 — intervention group
Group type: EXPERIMENTAL
Intervention: fish oil
Number of subjects: 10
Study 2676659 — intervention group
Group type: EXPERIMENTAL
Intervention: safflower oil
Number of subjects: 10
Study 201203 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormone treatment
Number of subjects: 60
Study 201203 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate (CaCO3) treatment
Number of subjects: 60
Study 201203 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 31429198 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy
Number of subjects: 351
Study 31429198 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy
Number of subjects: 351
Study 31429198 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic partial meniscectomy (as-treated)
Number of subjects: 351
Study 31429198 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (as-treated)
Number of subjects: 351
Study 31031579 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS
Number of subjects: 18
Study 31031579 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS
Number of subjects: 18
Study 31031579 — intervention group
Group type: COMPARATOR
Intervention: Sham HD-tDCS
Number of subjects: 18
Study 28994678 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin (continuous infusion)
Number of subjects: 56
Study 28994678 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg tablets twice daily)
Number of subjects: 56
Study 28994678 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 56
Study 26223240 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE diet (60% carbohydrate/25% fat/15% protein)
Number of subjects: 12
Study 26223240 — intervention group
Group type: COMPARATOR
Intervention: LC/CONV diet (40% carbohydrate/45% fat/15% protein)
Number of subjects: 12
Study 24410251 — intervention group
Group type: EXPERIMENTAL
Intervention: RRR‐HIV intervention (HIV educational video, five group sessions, one postrelease booster session)
Number of subjects: 444
Study 24410251 — intervention group
Group type: COMPARATOR
Intervention: Control condition (HIV educational video)
Number of subjects: 444
Study 22890220 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based exercise intervention
Number of subjects: 130
Study 22890220 — intervention group
Group type: COMPARATOR
Intervention: Wellness/support contact control
Number of subjects: 130
Study 19321398 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure of CBD
Number of subjects: 35
Study 19321398 — intervention group
Group type: COMPARATOR
Intervention: T-tube drainage
Number of subjects: 35
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab
Number of subjects: 0
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib
Number of subjects: 0
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 0
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 0
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 17250464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 0
Study 15736476 — intervention group
Group type: EXPERIMENTAL
Intervention: TXT plus CBG
Number of subjects: 70
Study 15736476 — intervention group
Group type: COMPARATOR
Intervention: TXT alone
Number of subjects: 70
Study 11554671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle activation of positive stereotypes
Number of subjects: 3
Study 11554671 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtle activation of negative stereotypes
Number of subjects: 3
Study 11554671 — intervention group
Group type: COMPARATOR
Intervention: Children in upper elementary grades (grades 3‐5)
Number of subjects: 3
Study 9371205 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental smoking habits (not specified dosage or duration)
Number of subjects: 501
Study 9371205 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental cotinine levels and amount smoked in the home
Number of subjects: 501
Study 9371205 — intervention group
Group type: EXPERIMENTAL
Intervention: Home environment (presence of a garden)
Number of subjects: 501
Study 7631069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal dopaminergic tissue implants by the open microsurgical technique
Number of subjects: 46
Study 7631069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal mesencephalic cell suspension transplants (7 unilateral and 9 bilateral)
Number of subjects: 46
Study 7631069 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic selective thalamotomy with microelectrode recording
Number of subjects: 46
Study 3681498 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 ppm acetone
Number of subjects: 70
Study 3681498 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppm methyl ethyl ketone
Number of subjects: 70
Study 3681498 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 ppm acetone/100 ppm methyl ethyl ketone
Number of subjects: 70
Study 3681498 — intervention group
Group type: COMPARATOR
Intervention: chemical placebo
Number of subjects: 70
Study 30048341 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial fitting group (group A)
Number of subjects: 100
Study 30048341 — intervention group
Group type: EXPERIMENTAL
Intervention: Software fitting group (group B)
Number of subjects: 100
Study 25922474 — intervention group
Group type: EXPERIMENTAL
Intervention: Day surgery
Number of subjects: 78
Study 25922474 — intervention group
Group type: COMPARATOR
Intervention: One night hospital stay
Number of subjects: 78
Study 25730930 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training (natural walking at 60% of maximum heart rate)
Number of subjects: 110
Study 25730930 — intervention group
Group type: COMPARATOR
Intervention: Control group (medicamental therapy only)
Number of subjects: 110
Study 22913492 — intervention group
Group type: EXPERIMENTAL
Intervention: (90)Y‐RE
Number of subjects: 140
Study 22913492 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 140
Study 20005079 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiepileptic drug treatment
Number of subjects: 125
Study 17076917 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive self-therapy (CST)
Number of subjects: 151
Study 17076917 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 151
Study 16383096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention program based on the Theory of Planned Behavior, including posters and lectures promoting healthy eating for 12 weeks
Number of subjects: 335
Study 16383096 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 335
Study 12062150 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological correlates of conscious change detection
Number of subjects: 0
Study 12062150 — intervention group
Group type: COMPARATOR
Intervention: Electrophysiological correlates of change blindness
Number of subjects: 0
Study 7783410 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (D)
Number of subjects: 64
Study 7783410 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 64
Study 2203556 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg, alternate-day intake)
Number of subjects: 22071
Study 2203556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22071
Study 360766 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiethylperazine 6.5 mg, 2 capsules a day for 5 days
Number of subjects: 40
Study 360766 — intervention group
Group type: COMPARATOR
Intervention: Meclizine 25 mg, 2 capsules a day for 5 days
Number of subjects: 40
Study 360766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Thiethylperazine and Meclizine)
Number of subjects: 40
Study 31596244 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedical emergency service
Number of subjects: 6265
Study 27860389 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg
Number of subjects: 175
Study 27860389 — intervention group
Group type: EXPERIMENTAL
Intervention: Canrenone 100 mg
Number of subjects: 175
Study 26845030 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Number of subjects: 0
Study 26845030 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 0
Study 23510444 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment (mean weight-adjusted total daily dose at end of phase II was 27.8 mg/kg/day, average lithium concentration of 1.0 mEq/L)
Number of subjects: 41
Study 23510444 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive psychotropic medications (up to two could be prescribed)
Number of subjects: 41
Study 20558528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (HE)
Number of subjects: 90
Study 20558528 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity exercise (ME)
Number of subjects: 90
Study 20558528 — intervention group
Group type: COMPARATOR
Intervention: No exercise/rest (NE)
Number of subjects: 90
Study 19576495 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular therapy with latanoprost
Number of subjects: 26
Study 19576495 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocular trial eye
Number of subjects: 26
Study 17241503 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg kg(‐1) (Group 3)
Number of subjects: 150
Study 17241503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 microg kg(‐1) plus lidocaine 0.25 mg kg(‐1) (Group 4)
Number of subjects: 150
Study 17241503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 microg kg(‐1) plus lidocaine 0.5 mg kg(‐1) (Group 5)
Number of subjects: 150
Study 17241503 — intervention group
Group type: COMPARATOR
Intervention: Saline (Group 1)
Number of subjects: 150
Study 17241503 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 microg kg(‐1) (Group 2)
Number of subjects: 150
Study 17241503 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of withdrawal movements due to rocuronium
Number of subjects: 150
Study 17241503 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of withdrawal movement after rocuronium injection
Number of subjects: 150
Study 15017827 — intervention group
Group type: EXPERIMENTAL
Intervention: Approach-focused RP intervention
Number of subjects: 47
Study 15017827 — intervention group
Group type: COMPARATOR
Intervention: Avoidance-focused RP intervention
Number of subjects: 47
Study 11136682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (lifestyle changes)
Number of subjects: 275
Study 11136682 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only group (control)
Number of subjects: 275
Study 9681721 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with backfiltration (Group II, 12 patients)
Number of subjects: 65
Study 9681721 — intervention group
Group type: COMPARATOR
Intervention: Haemodiafiltration without backfiltration (Group I, 16 patients)
Number of subjects: 65
Study 9681721 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodiafiltration with backfiltration (Group III, 27 patients)
Number of subjects: 65
Study 9681721 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis (Group IV, 10 patients)
Number of subjects: 65
Study 9681721 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (Group V, 10 patients)
Number of subjects: 65
Study 7973771 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with cisplatin 50 mg/m2 days 1 and 8 every 4 weeks during the 16 weeks, and vinorelbine 30 mg/m2 weekly for 16 weeks.
Number of subjects: 17
Study 7973771 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m2 weekly for 5 weeks with a 50% dose reduction planned for week 2 only, in combination with cisplatin 100 mg/m2 during weeks 1 and 5, and accelerated fractionation thoracic irradiation during weeks 7 to 10.
Number of subjects: 17
Study 7973771 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group).
Number of subjects: 17
Study 2529150 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17,21‐dipropionate (Bet) and fluprednidene 21‐acetate (Flu) applied in a 1:1 and 1:2 rhythm under occlusive dressing for 8 weeks.
Number of subjects: 0
Study 2529150 — intervention group
Group type: COMPARATOR
Intervention: Continuous application (CA) of Bet and Flu for 3 weeks.
Number of subjects: 0
Study 2529150 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 17‐butyrate, betamethasone 17‐valerate, desoxymethasone, and hydrocortisone tested in a 5:9 regimen under occlusive dressing for 3 months.
Number of subjects: 0
Study 5090667 — intervention group
Group type: EXPERIMENTAL
Intervention: Water miscible preparation of α‐tocopheryl acetate, daily dose of 1 mg/kg body weight
Number of subjects: 0
Study 5090667 — intervention group
Group type: COMPARATOR
Intervention: Fat soluble preparation of α‐tocopheryl acetate
Number of subjects: 0
Study 31725319 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium intake (15 g/day for 7 days)
Number of subjects: 13
Study 31306302 — intervention group
Group type: EXPERIMENTAL
Intervention: 30FAIL (30% 1RM to volitional fatigue)
Number of subjects: 21
Study 31306302 — intervention group
Group type: EXPERIMENTAL
Intervention: 80FAIL (80% 1RM performed to volitional fatigue)
Number of subjects: 21
Study 31306302 — intervention group
Group type: COMPARATOR
Intervention: 30WM (30% 1RM with volume matched to 80FAIL)
Number of subjects: 21
Study 28101947 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser (ERL)
Number of subjects: 15
Study 28101947 — intervention group
Group type: COMPARATOR
Intervention: Plastic curettes + cotton pellets + sterile saline (CPS)
Number of subjects: 15
Study 24794517 — intervention group
Group type: EXPERIMENTAL
Intervention: SMR neurofeedback training
Number of subjects: 20
Study 24794517 — intervention group
Group type: COMPARATOR
Intervention: Sham feedback
Number of subjects: 20
Study 23521322 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin
Number of subjects: 0
Study 23521322 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21603848 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified constraint-induced movement therapy
Number of subjects: 30
Study 21603848 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive conventional rehabilitation
Number of subjects: 30
Study 21603848 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 30
Study 21603848 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 30
Study 19531784 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B hemoperfusion (2 sessions)
Number of subjects: 64
Study 19531784 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 64
Study 17074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide at 7.5 ng/kg/min
Number of subjects: 221
Study 17074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide at 15 ng/kg/min
Number of subjects: 221
Study 17074775 — intervention group
Group type: EXPERIMENTAL
Intervention: Ularitide at 30 ng/kg/min
Number of subjects: 221
Study 17074775 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 15063145 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous Communication (SC)
Number of subjects: 12
Study 15063145 — intervention group
Group type: COMPARATOR
Intervention: Speech Alone (SA)
Number of subjects: 12
Study 11179544 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation dihydropyridine calcium channel blockers
Number of subjects: 0
Study 9258853 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% carbohydrate solution
Number of subjects: 8
Study 9258853 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 8
Study 8070007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2) administered intravenously
Number of subjects: 16
Study 8070007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2) administered via hepatic artery
Number of subjects: 16
Study 8070007 — intervention group
Group type: EXPERIMENTAL
Intervention: Lignocaine (1 mg/kg) administered intravenously
Number of subjects: 16
Study 8070007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (75 mg/m2)
Number of subjects: 16
Study 8070007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epirubicin
Number of subjects: 16
Study 8070007 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarterial epirubicin
Number of subjects: 16
Study 3343920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic weighing (HW) at residual volume (RV)
Number of subjects: 182
Study 3343920 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrostatic weighing (HW) at total lung capacity without head submersion (TLCNS)
Number of subjects: 182
Study 3343920 — intervention group
Group type: COMPARATOR
Intervention: Db from HW at RV
Number of subjects: 182
Study 3343920 — intervention group
Group type: COMPARATOR
Intervention: pDb from HW at TLCNS
Number of subjects: 182
Study 3343920 — intervention group
Group type: EXPERIMENTAL
Intervention: Test-re-test data for TLCNS procedure
Number of subjects: 182
Study 3343920 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean percent fat for RV and TLCNS
Number of subjects: 182
Study 31738621 — intervention group
Group type: EXPERIMENTAL
Intervention: FDA approved medications for IBS-D
Number of subjects: 0
Study 31738621 — intervention group
Group type: EXPERIMENTAL
Intervention: Emerging therapies for IBS-D
Number of subjects: 0
Study 29630479 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational sitting time (measured with activPAL3 monitor)
Number of subjects: 216
Study 29630479 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational standing and stepping time (measured with activPAL3 monitor)
Number of subjects: 216
Study 29630479 — intervention group
Group type: EXPERIMENTAL
Intervention: Total activity duration
Number of subjects: 216
Study 28365177 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (cholecalciferol; 100,000 IU, once-monthly)
Number of subjects: 87
Study 28365177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 24689780 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 25
Study 24689780 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 23982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate 25 mg V daily
Number of subjects: 16
Study 23982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate 50 mg V daily
Number of subjects: 16
Study 23982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate 100 mg V daily
Number of subjects: 16
Study 23982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemic‐hyperinsulinemic clamp
Number of subjects: 16
Study 23982218 — intervention group
Group type: EXPERIMENTAL
Intervention: Globulin and glycohemoglobin levels
Number of subjects: 16
Study 21358385 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic Care Program for Dementia (SCPD)
Number of subjects: 295
Study 21358385 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 295
Study 19040173 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicare Health Support (MHS) pilot program
Number of subjects: 0
Study 19040173 — intervention group
Group type: EXPERIMENTAL
Intervention: Care management services
Number of subjects: 0
Study 17006356 — intervention group
Group type: EXPERIMENTAL
Intervention: Mime therapy
Number of subjects: 48
Study 12940805 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5-mg tablet)
Number of subjects: 12
Study 12940805 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500-mg capsule)
Number of subjects: 12
Study 10861337 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation (8.425 g choline citrate)
Number of subjects: 14
Study 10861337 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 14
Study 10861337 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline supplementation
Number of subjects: 14
Study 9292451 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion for 30 min (WI)
Number of subjects: 6
Study 9292451 — intervention group
Group type: EXPERIMENTAL
Intervention: Water immersion for 30 min with thigh cuff inflation (WI+Occl)
Number of subjects: 6
Study 9292451 — intervention group
Group type: COMPARATOR
Intervention: Seated nonimmersed control with 15 min of thigh cuff inflation (Occl)
Number of subjects: 6
Study 8210986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A retention enemas (250 mg daily)
Number of subjects: 13
Study 3538802 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion strategy
Number of subjects: 884
Study 3538802 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 884